SNRK

SNF-related serine/threonine-protein kinase

511 patent compounds predicted against SNRK, 355 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8987884	0.67	1/20
SCHEMBL28692611	0.62	1/20
SCHEMBL29373901	0.62	1/20
SCHEMBL13451637	0.62	1/20
SCHEMBL27925926	0.60	1/20
SCHEMBL2185694	0.60	1/20
SCHEMBL31240719	0.59	1/20
SCHEMBL3423175	0.58	1/20
SCHEMBL28587243	0.58	1/20
SCHEMBL2038480	0.58	1/20
SCHEMBL8240613	0.58	1/20
SCHEMBL12461473	0.58	1/20
SCHEMBL13922914	0.58	1/20
SCHEMBL21348793	0.58	1/20
SCHEMBL6584957	0.57	1/20
SCHEMBL1431669	0.57	1/20
SCHEMBL5197796	0.57	1/20
SCHEMBL9367263	0.57	1/20
SCHEMBL12062262	0.57	1/20
SCHEMBL22281368	0.57	1/20

Germline variants in SNRK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full SNRK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to SNRK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Genetic-specific Effects of Fructose on Liver Lipogenesis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SNRK binder may also engage these)

Protein	Name	Similarity
Q63553	—	1.000	Q63553 →
Q8VDU5	—	1.000	Q8VDU5 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	1.000	landscape →
A7MBB4	—	0.999	A7MBB4 →
Q6DBX4	—	0.998	Q6DBX4 →
O01700	—	0.998	O01700 →
Q5R8X7	—	0.997	Q5R8X7 →
A0A1D9QMS2	—	0.997	A0A1D9QMS2 →
Q66HD5	—	0.997	Q66HD5 →
Q92539	—	0.997	Q92539 →
Q641K5	—	0.997	Q641K5 →
A8WRV1	—	0.997	A8WRV1 →
Q0DCT8	—	0.997	Q0DCT8 →
P46200	—	0.997	P46200 →
A8XQD5	—	0.996	A8XQD5 →
Q3ULB5	—	0.996	Q3ULB5 →
STK33	Serine/threonine-protein kinase 33	0.996	landscape →
F4J6F6	—	0.996	F4J6F6 →
P14646	—	0.996	P14646 →
Q99PI5	—	0.996	Q99PI5 →
Q6NN85	—	0.996	Q6NN85 →
Q5VUJ5	—	0.996	Q5VUJ5 →
PDE4B	3',5'-cyclic-AMP phosphodiesterase 4B	0.996	landscape →
Q9SB51	—	0.996	Q9SB51 →
Q6NTJ3	—	0.995	Q6NTJ3 →
Q924U5	—	0.995	Q924U5 →
P10244	—	0.995	P10244 →
KAT6B	Histone acetyltransferase KAT6B	0.995	landscape →
B3M301	—	0.995	B3M301 →
P49844	—	0.995	P49844 →